Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial

DSpace Repository

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial

Author: Chi, Kim N.; Higano, Celestia S.; Blumenstein, Brent; Ferrero, Jean-Marc; Reeves, James; Feyerabend, Susan; Gravis, Gwenaelle; Merseburger, Axel S.; Stenzl, Arnulf; Bergman, Andries M.; Mukherjee, Som D.; Zalewski, Pawel; Saad, Fred; Jacobs, Cindy; Gleave, Martin; de Bono, Johann S.
Tübinger Autor(en):
Feyerabend, Susan
Stenzl, Arnulf
Published in: Lancet Oncology (2017), Bd. 18, H. 4, S. 473-485
Verlagsangabe: Elsevier Science Inc
Language: English
Full text: http://dx.doi.org/10.1016/S1470-2045(17)30168-7
ISSN: 1474-5488
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)